Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRO STATIN versus ILOSONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRO STATIN versus ILOSONE.
ERYTHRO-STATIN vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
200 mg intravenously once daily.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic